Insider Selling: OS Therapies Inc (NYSE:OSTX) Major Shareholder Sells $284,000.00 in Stock

OS Therapies Inc (NYSE:OSTX) major shareholder Shalom Auerbach sold 100,000 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $2.84, for a total value of $284,000.00. Following the transaction, the insider now directly owns 2,431,211 shares in the company, valued at approximately $6,904,639.24. This represents a 3.95 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Shalom Auerbach also recently made the following trade(s):

• On Wednesday, January 15th, Shalom Auerbach sold 16,720 shares of OS Therapies stock. The shares were sold at an average price of $6.74, for a total value of $112,692.80.

OS Therapies Stock Performance

Shares of OSTX opened at $1.89 on Friday. OS Therapies Inc has a 12 month low of $1.58 and a 12 month high of $7.00. The stock has a fifty day moving average price of $3.31 and a 200 day moving average price of $3.14.

Hedge Funds Weigh In On OS Therapies

An institutional investor recently raised its position in OS Therapies stock. CM Management LLC raised its holdings in shares of OS Therapies Inc (NYSE:OSTX) by 120.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 110,044 shares of the company’s stock after acquiring an additional 60,044 shares during the period. CM Management LLC owned approximately 0.51% of OS Therapies worth $471,000 as of its most recent SEC filing.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on OSTX shares. Maxim Group boosted their target price on shares of OS Therapies from $8.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, January 16th. D. Boral Capital reaffirmed a “buy” rating and set a $20.00 price objective on shares of OS Therapies in a research report on Thursday.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.